News & events Upcoming events May 26, 2022 - May 28, 2022 Pneumomedicina 2022 Milano, Italy More info and meet us there May 27, 2022 - May 27, 2022 XIII Convegno di Immunometria del Sud Italia Matera, Italy More info and meet us there Jun 1, 2022 - Jun 3, 2022 BcnPit - XII Biennial Conference Barcelona, Spain More info and meet us there See all upcoming events Latest news May 5, 2022 Lumipulse® G β-Amyloid Ratio (1-42/1-40) in vitro diagnostic test receives FDA marketing authorization for the assessment of Alzheimer’s disease in the United States MALVERN, Pa., USA - Fujirebio Diagnostics, Inc., a consolidated subsidiary of H.U. Group Holdings, Inc., today announced that the U.S. Food... Read more Apr 14, 2022 Lumipulse® G SARS-CoV-2 Ag included in EU’s common list of COVID-19 laboratory based antigenic assays The Lumipulse G SARS-CoV-2 Ag assay is included in the list of mutually recognised COVID-19 laboratory based antigenic assay as agreed by... Read more Mar 30, 2022 Fujirebio confirms its engagement in blood-based Alzheimer’s disease biomarker testing with the launch of the fully automated Lumipulse® G β-Amyloid 1-42 and β-Amyloid 1-40 Plasma assays for Research Use Only H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G β-Amyloid 1-42 Plasma... Read more Mar 1, 2022 Fujirebio enters the field of fully automated blood-based Alzheimer’s disease biomarker testing with the release of the Lumipulse® G pTau 181 Plasma assay for Research Use Only Gent, Belgium, Malvern PA, USA, and Tokyo, Japan, March 1st, 2022 – H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today... Read more Jan 18, 2022 Fujirebio Europe launches the RoboBlot™ instrument, a fully automated solution for INNO-LIA® Score assays Gent, Belgium - January 18, 2022: Fujirebio Europe announced today the commercial launch of the RoboBlot instrument, a closed system for the... Read more Nov 19, 2021 Fujirebio Europe confirms engagement in new pathways for Alzheimer’s disease research and launches INNOTEST® assays for the two promising biomarkers NPTX2 and sTREM2 Fujirebio Europe today announced the commercial launch of two new cerebrospinal fluid (CSF) based immunoassays for the novel neurology... Read more Load More
May 27, 2022 - May 27, 2022 XIII Convegno di Immunometria del Sud Italia Matera, Italy More info and meet us there
Jun 1, 2022 - Jun 3, 2022 BcnPit - XII Biennial Conference Barcelona, Spain More info and meet us there
May 5, 2022 Lumipulse® G β-Amyloid Ratio (1-42/1-40) in vitro diagnostic test receives FDA marketing authorization for the assessment of Alzheimer’s disease in the United States MALVERN, Pa., USA - Fujirebio Diagnostics, Inc., a consolidated subsidiary of H.U. Group Holdings, Inc., today announced that the U.S. Food... Read more
Apr 14, 2022 Lumipulse® G SARS-CoV-2 Ag included in EU’s common list of COVID-19 laboratory based antigenic assays The Lumipulse G SARS-CoV-2 Ag assay is included in the list of mutually recognised COVID-19 laboratory based antigenic assay as agreed by... Read more
Mar 30, 2022 Fujirebio confirms its engagement in blood-based Alzheimer’s disease biomarker testing with the launch of the fully automated Lumipulse® G β-Amyloid 1-42 and β-Amyloid 1-40 Plasma assays for Research Use Only H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G β-Amyloid 1-42 Plasma... Read more
Mar 1, 2022 Fujirebio enters the field of fully automated blood-based Alzheimer’s disease biomarker testing with the release of the Lumipulse® G pTau 181 Plasma assay for Research Use Only Gent, Belgium, Malvern PA, USA, and Tokyo, Japan, March 1st, 2022 – H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today... Read more
Jan 18, 2022 Fujirebio Europe launches the RoboBlot™ instrument, a fully automated solution for INNO-LIA® Score assays Gent, Belgium - January 18, 2022: Fujirebio Europe announced today the commercial launch of the RoboBlot instrument, a closed system for the... Read more
Nov 19, 2021 Fujirebio Europe confirms engagement in new pathways for Alzheimer’s disease research and launches INNOTEST® assays for the two promising biomarkers NPTX2 and sTREM2 Fujirebio Europe today announced the commercial launch of two new cerebrospinal fluid (CSF) based immunoassays for the novel neurology... Read more
